Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KA Phillips; RL Milne; MA Rookus; MB Daly; AC Antoniou; S Peock; D Frost; DF Easton; S Ellis; ML Friedlander; SS Buys; N Andrieu; C Noguès; D Stoppa-Lyonnet; V Bonadona; P Pujol; SA McLachlan; EM John; MJ Hooning; C Seynaeve; RAEM Tollenaar; DE Goldgar; MB Terry; T Caldes; PC Weideman; IL Andrulis; CF Singer; K Birch; J Simard; MC Southey; HL Olsson; A Jakubowska; E Olah; AM Gerdes; L Foretova; JL Hopper

Journal article

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KA Phillips, RL Milne, MA Rookus, MB Daly, AC Antoniou, S Peock, D Frost, DF Easton, S Ellis, ML Friedlander, SS Buys, N Andrieu, C Noguès, D Stoppa-Lyonnet, V Bonadona, P Pujol, SA McLachlan, EM John, MJ Hooning, C Seynaeve Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2013

DOI: 10.1200/JCO.2012.47.8313

Abstract

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated us..

View full abstract

University of Melbourne Researchers

Kelly Phillips Author

Roger Milne Author

Sue-Anne McLachlan Author

Melissa Southey Author

Related Projects (1)

REDUCING THE BURDEN OF BREAST CANCER FOR AUSTRALIAN WOMEN AND THEIR FAMILIES

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

Supported by the (Australian) National Breast Cancer Foundation and Cancer Australia Grant No. 628333. International BRCA1 and BRCA2 Carrier Cohort Study (IBCCS) -Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers, UK (EMBRACE) is supported by Cancer Research UK Grants No. C1287/A10118 and C1287/A11990. IBCCS-Gene Etude Prospective Sein Ovaire, France (GENEPSO) is supported by the Fondation de France and the Ligue Nationale Contre le Cancer. IBCCS-Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) is supported by Dutch Cancer Society Grants No. NKI1998 1854, NKI2004-3088, NKI2007-3756 and the Netherlands Organization for Scientific Research Grant No. NWO/91109024. IBCCS-Interdisciplinary Health Research Internal Team Breast Cancer Susceptibility Study (INHERIT) was supported by the Canadian Institutes of Health Research for the INHERIT BRCAs research program (Grant No. CRT43822) and Canadian Institute Health Research (CIHR) Team in Familial Risks of Breast Cancer program (Grant No. CRN87521), the Canadian Breast Cancer Research Alliance (Grant No. 019511), and the Ministry of Economic Development, Innovation and Export Trade (Grant No. PSR-SIIRI 701). IBCCS-National Institute of Oncology (NIO) Hungary was funded by European Against Cancer (subcontract between International Agency for Research on Cancer Lyon and NIO Budapest). This study at NIO, Budapest, Hungary, was supported in part by Norwegian European Economic Area (EEA) Financial Mechanism (Grant No. HU0115/NA/2008-3/OP-9). IBCCS-Brno, Masaryk Memorial Cancer Institute (MMCI), Czech Republic was supported by IBCCS and by the European Regional Development Fund and the State Budget of the Czech Republic (Regional Center for Applied Molecular Oncology [RECAMO], Grant No. CZ.1.05/2.1.00/03.0101). IBCCS-Molecular Oncology Laboratory, Madrid (MOL) was supported by Grant No. RD06/0020/0021 from Red Tematica Investigacion Cooperative en Cancer (RTICC; ISCIII), Spanish Ministry of Economy and Competitivity. The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) and the kConFab Follow-Up Study are supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council, and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The Breast Cancer Family Registry (BCFR) was supported by the National Cancer Institute, National Institutes of Health under Grant No. UMICA164920 and through cooperative agreements with members of the BCFR and principal investigators, including Cancer Care Ontario (Grant No. U01 CA69467), Cancer Prevention Institute of California (Grant No. U01 CA69417), Columbia University (Grant No. U01 CA69398), Fox Chase Cancer Center (Grant No. U01 CA69631), Huntsman Cancer Institute (Grant No. U01 CA69446), the University of Melbourne (Grant No. U01 CA69638), and Georgetown University Medical Center Informatics Support Center (Grant No. HHSN261200900010C).